Aptevo Therapeutics (APVO) shares were surging early Thursday after the company said all of the patients with acute myeloid leukemia treated with its mipletamig bispecific antibody achieved remission within 30 days of treatment in a phase 1b trial, including two patients in the cohort who experienced complete remission with 100% elimination of cancer cells.
The results build on data from the company's prior trial of the immune-oncology therapeutics platform, where 100% of the frontline patients also achieved remission, it said.
The phase 1b/2 dose optimization trial is investigating mipletamig as frontline therapy in up to 39 patients across five dosing levels in combination with venetoclax and azacitidine, which are the current standard of care for acute myeloid leukemia.
Price: 11.99, Change: +1.98, Percent Change: +19.78
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。